Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5197271 | 0.90 | HRH3 (0.64) | HRH3HRH1CYP2D6 | |
| SCHEMBL5662176 | 0.89 | HRH3 (0.66) | HRH3HRH1CYP2D6 | |
| Hydrochloric Acid SCHEMBL5662921 | 0.88 | HRH3 (0.65) | HRH3HRH1CYP2D6 | |
| SCHEMBL5662222 | 0.87 | HRH3 (0.58) | HRH3HRH1CYP2D6 | |
| SCHEMBL5663374 | 0.86 | HRH3 (0.53) | HRH3HRH1CYP2D6 | |
| SCHEMBL5663005 | 0.84 | HRH3 (0.51) | HRH3HRH1CYP2D6 | |
| SCHEMBL5663023 | 0.82 | HRH3 (0.50) | HRH3HRH1CYP2D6 | |
| SCHEMBL2275230 | 0.79 | HRH3 (0.55) | HRH3HRH1CYP2D6 | |
| SCHEMBL5663787 | 0.79 | HRH3 (0.52) | HRH3HRH1CYP2D6 | |
| SCHEMBL2264332 | 0.78 | HRH3 (0.54) | HRH3HRH1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-09-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885HRH1 3/4885CYP2D6 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.